Meriva curcumin-phospholipid complex, 2 g/day, as add-on therapy × Improvement of PASI in mild-to-moderate plaque psoriasis

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionWhich PASI add-on effect is presented?Required	The original claim concerns PASI improvement in mild-to-moderate plaque psoriasis. Scope is the add-on effect of a specific phospholipid complex alongside topical steroids. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	12-week PASI with Meriva plus topical steroids versus common topical steroids alone	Material needed: Original-trial intervention, comparator and endpoint specifications. This records needed materials; no new research was executed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionWhich psoriasis population is included?Required	The retained scope describes adults with mild-to-moderate plaque psoriasis and PASI below 10. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Eligibility of adults with mild-to-moderate plaque psoriasis and PASI below 10	Material needed: Diagnosis, eligibility and baseline-characteristic tables. This records needed materials; no new research was executed.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionWhat are the Meriva carrier and quantified composition?Required	The retained formulation is a commercial phospholipid phytosome with approximately 20% curcuminoids, using a soy-lecithin carrier. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Commercial phospholipid phytosome, approximately 20% curcuminoids and soy lecithin	Material needed: Product, batch and ingredient-quantification specifications. This records needed materials; no new research was executed.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionIs oral Meriva interchangeable with other curcumin products?Required	The selected intervention is oral Meriva. The original record limits interchangeability across other formulations and routes. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing oral phospholipid complexes from conventional powder, nano, micellar, piperine-combination and topical products	Material needed: Direct comparisons for each product and route. This records needed materials; no new research was executed.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionWhat does 2 g/day represent?Required	The retained dose is 2 g/day of Meriva. It is not equated to 2 g of conventional curcumin. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	2 g/day of the Meriva product, with actual dosing and adherence	Material needed: Product amounts, dosing adherence and change records. This records needed materials; no new research was executed.
6	Unverified	Full text not readStored summary read	N06 · Evidence conditionDoes benefit persist beyond 12 weeks?Required	The retained duration is 12 weeks of treatment and follow-up, with long-term relapse described as unknown. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	12 weeks of treatment/follow-up and subsequent persistence/relapse	Material needed: Visit schedules and post-treatment follow-up. This records needed materials; no new research was executed.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionHow was common topical-steroid treatment aligned?Required	The record states that both groups used topical steroids and differed by added Meriva. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Topical-steroid ingredients, potency, sites, use and changes in both groups	Material needed: Topical-steroid and rescue-treatment records. This records needed materials; no new research was executed.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionDid the control group receive an oral placebo?Required	The original record describes a comparison against topical steroids alone without placebo. The retained evidence also describes a no-add-on control. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing no-add-on controls from add-on-placebo controls	Material needed: Control-intervention, visit and management specifications. This records needed materials; no new research was executed.
9	Partly verified	Full text not readStored summary read	N09 · Evidence conditionWhat is the identity of the direct report?Required	The stored bibliography records Antiga 2015, PMID 26090395, PMCID PMC4450233, DOI 10.1155/2015/283634. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Retained links among the Antiga report title, PMID, PMCID and DOI	Material needed: Original paper and bibliographic records. This records needed materials; no new research was executed.
10	Unverified	Full text not readStored summary read	N10 · Evidence conditionWere registration and a prespecified study plan provided?Required	The retained trial-registration field remains unverified, and the citation contains no registration identifier. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Registration identifiers/timing, protocol and amendments	Material needed: Original registration, protocol and amendments. This records needed materials; no new research was executed.
11	Partly verified	Full text not readStored summary read	N11 · Evidence conditionWhat is the hierarchy of PASI change and PASI75?Required	The retained endpoint is PASI change at 12 weeks, with PASI75 described as secondary. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing 12-week PASI change from secondary PASI75 results	Material needed: Endpoint hierarchy in registration, protocol and SAP. This records needed materials; no new research was executed.
12	Partly verified	Full text not readStored summary read	N12 · Evidence conditionWhat were the allocation and concealment methods?Required	The report is retained as a randomized add-on trial. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Randomization procedures, allocation concealment and participant flow	Material needed: Allocation methods and participant-flow diagrams. This records needed materials; no new research was executed.
13	Unverified	Full text not readStored summary read	N13 · Evidence conditionHow are reported double blinding and the no-add-on control interpreted?Required	The retained evidence describes a trial reported as double-blind, with a no-add-on control. Reported wording does not establish actual fulfillment of blinding. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Blinded parties, maintenance/unblinding and actual control interventions	Material needed: Original blinding-party, placebo and assessment procedures. This records needed materials; no new research was executed.
14	Partly verified	Full text not readStored summary read	N14 · Evidence conditionWhat denominators do 63 assigned and 49 completed represent?Required	The retained sample description is 63 assigned participants and 49 completers. Completer results are not relabeled as analyses of all assigned participants. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing allocated, completed and endpoint-specific analysis denominators	Material needed: Group flow, analysis populations and result tables. This records needed materials; no new research was executed.
15	Unverified	Full text not readStored summary read	N15 · Evidence conditionWhat does the original 22% attrition describe?Required	The original record describes 22% attrition. This historical value is retained without recalculation. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Attrition reasons, distribution by group and the recorded 22%	Material needed: Attrition/discontinuation reasons and group flow. This records needed materials; no new research was executed.
16	Unverified	Full text not readStored summary read	N16 · Evidence conditionWhat are the completer analysis and missing-data assumptions?Required	The original record describes positive PASI results among 49 completers. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Results in 49 completers, ITT, missing-data handling and analysis models	Material needed: SAP, analysis populations and missing-data material. This records needed materials; no new research was executed.
17	Partly verified	Full text not readStored summary read	N17 · Evidence conditionHow was PASI measured?Required	The selected endpoint is PASI change at 12 weeks. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	PASI scoring, baseline values, assessors and 12-week measurement	Material needed: Scale, baseline values, assessment procedures and result tables. This records needed materials; no new research was executed.
18	Partly verified	Full text not readStored summary read	N18 · Evidence conditionWhat underlies decreases in both groups and the larger add-on decrease?Required	The stored result is a narrative of decreases in both groups, with a larger decrease in the Meriva add-on arm. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Group PASI changes and the exact between-group add-on effect	Material needed: Original group tables, between-group effects and analysis output. This records needed materials; no new research was executed.
19	Unverified	Full text not readStored summary read	N19 · Evidence conditionIs an exact adjusted-effect interval available?Required	The stored result leaves the exact adjusted CI unverified. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Between-group adjusted PASI estimate and 95% CI	Material needed: Between-group adjusted estimates, 95% CIs and models. This records needed materials; no new research was executed.
20	Unverified	Full text not readStored summary read	N20 · Evidence conditionWhat are the tests, multiplicity and analysis timepoints?Required	The current summary retains a directionally positive narrative. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Exact PASI tests, P values, adjustment and prespecified plans	Material needed: SAP, all tests and result tables. This records needed materials; no new research was executed.
21	Unverified	Full text not readStored summary read	N21 · Evidence conditionIs the PASI difference clinically important?Required	The retained record centers on PASI and separates quality of life. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Patient importance, responders and quality of life for scale changes	Material needed: Important-difference, patient-reported and quality-of-life material. This records needed materials; no new research was executed.
22	Partly verified	Full text not readStored summary read	N22 · Evidence conditionDoes PASI75 replace the central result?Required	PASI75 is retained as a secondary result. It does not replace prespecification or the exact effect for PASI change. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Denominators, response and intervals for secondary PASI75	Material needed: PASI75 result tables and prespecified hierarchy. This records needed materials; no new research was executed.
23	Partly verified	Full text not readStored summary read	N23 · Evidence conditionIs IL-22 direction the same outcome as the PASI effect?Required	The original record describes concordant directions for PASI reduction and IL-22. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing the IL-22 mechanistic marker from the PASI clinical scale	Material needed: Separate mechanistic and PASI result tables. This records needed materials; no new research was executed.
24	Unverified	Full text not readStored summary read	N24 · Evidence conditionIs there independent replication for the same formulation?Required	The retained evidence and citation describe one direct report. Multiple outcomes within one report are not counted as multiple trials. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Report-to-trial links and formulation-specific independent replication	Material needed: Replication reports and trial links under the same conditions. This records needed materials; no new research was executed.
25	Partly verified	Full text not readStored summary read	N25 · Evidence conditionWhat information underlies manufacturer Indena support?Required	The retained funding description records Indena support and product-related interests. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Manufacturer funding, product support and research roles	Material needed: Original funding, product-support and manufacturer-role disclosures. This records needed materials; no new research was executed.
26	Unverified	Full text not readStored summary read	N26 · Evidence conditionAre product provision, employee authors and COI separately known?Required	Manufacturer-support wording is retained without establishing product provision, employee authorship or declared COI individually. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing product provision, author employment, COI declarations and funding	Material needed: Original product-provision, author-affiliation and COI disclosures. This records needed materials; no new research was executed.
27	Unverified	Full text not readStored summary read	N27 · Evidence conditionHow were short-term adverse events in the same population collected?Supplementary	The retained safety wording limits exclusion of long-term harms from 12-week material. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Event definitions, collection methods and group exposure denominators	Material needed: Adverse-event tables, collection methods and exposure denominators. This records needed materials; no new research was executed.
28	Unverified	Full text not readStored summary read	N28 · Evidence conditionAre long-term hepatic, biliary and bleeding risks answered?Supplementary	The original record says 12-week material cannot exclude long-term hepatic, biliary or bleeding risks. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Harms beyond 12 weeks, concomitant medicines and long-term follow-up	Material needed: Long-term harm, concomitant-medicine and follow-up material. This records needed materials; no new research was executed.
29	Unverified	Full text not readStored summary read	N29 · Evidence conditionWhat product condition underlies soy-lecithin allergy concerns?Supplementary	The retained record describes a soy-lecithin carrier and allergy checks depending on product composition. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Phospholipid-carrier composition and allergy populations/events	Material needed: Product composition, allergy criteria and event material. This records needed materials; no new research was executed.
30	Partly verified	Full text not readStored summary read	N30 · Evidence conditionCan findings extend to generic turmeric treatment or steroid replacement?Required	The original record limits extension to treatment with dietary turmeric/generic powder or replacement of topical steroids. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing add-on therapy from monotherapy and treatment replacement	Material needed: Direct monotherapy and replacement-treatment comparisons. This records needed materials; no new research was executed.
31	Partly verified	Full text not readStored summary read	N31 · Evidence conditionHow are current Korean/English records and the English correction retained?Required	Current Korean/English material and the correction of 1 English field are retained. Generic English wording does not substitute for verification of exact numbers or denominators. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Current English wording, generic evidence wording and correction of 1 field on 2026-09-14	Material needed: Before/after-correction and language-alignment material. This records needed materials; no new research was executed.
32	Partly verified	Full text not readStored summary read	N32 · Evidence conditionWhat are C/50, original axes and historical cross-checking?Required	C/50, all axes and historical cross-checking wording are retained as historical values. They are not inherited as completed current content review or fulfilled conditions. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original grade, score, axes including I0, E+ and C0, and historical records	Material needed: Review comments and future correction material. This records needed materials; no new research was executed.
33	Partly verified	Full text not readStored summary read	N33 · Evidence conditionWhat are the original dates, blank fields and actual reading scope?Required	The full retained record was used for preparation. Original verdict date 2026-09-08, correction date 2026-09-14 and blank original values remain preserved. S01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original verdict/correction dates, absence of additional selected questions, blank additional-review notes and external unread status	Material needed: Needed original material and study plans when provided. This records needed materials; no new research was executed.

No items match your search or filter.

33 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-09-08
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded.
Population: The retained population is adults with mild-to-moderate plaque psoriasis and PASI below 10. Diagnosis, baseline characteristics, history, prior treatments and exclusion criteria remain incompletely verified; scope is not extended to other severities or psoriasis types.
Ingredient, formulation and route: The record describes a commercial Meriva phospholipid phytosome containing Curcuma longa curcuminoids in a soy-lecithin carrier, with approximately 20% curcuminoids. Batches, measured amounts and bioavailability remain unverified; equivalence to other curcumin formulations is not established.
Dose: The original value is 2 g/day of the Meriva product. It is not equated to 2 g of conventional curcumin or converted into an active-ingredient amount. Actual dosing, adherence, changes and exposure remain unverified.
Comparator: The comparison is Meriva added to topical steroids common to both groups versus topical steroids alone. The record states that there was no oral add-on placebo; topical-agent ingredients, potency, use, changes and rescue treatment remain incompletely verified.
Measured outcome: The selected endpoint is PASI change at 12 weeks. Exact between-group adjusted estimates, 95% CIs, prespecified hierarchy, measurement and denominators remain unverified. Secondary PASI75, the mechanistic IL-22 marker and quality of life address separate questions.
Duration: The record describes 12 weeks of treatment and follow-up. Visit schedules, actual exposure, post-treatment persistence, relapse and long-term follow-up remain unverified; scope is not extended to long-term efficacy or safety.
Questions outside this scope: The original C/50/Caution and B/S/R1/I0/E+/B2/C0 are retained. Historical cross-checking and positive-result narratives are historical records, not current external original-source reading, reassessment or independent clinical certification.; 63 assigned participants, 49 completers and the original narrative of 22% attrition are retained separately as original values. Group analysis denominators, ITT and missing-data handling remain unverified; completer results are not relabeled as analyses of all assigned participants, and attrition is not recalculated.; The qualitative record describes decreases in both groups, with a larger decrease in the Meriva add-on arm. Exact between-group differences, adjustment models, 95% CIs and P values remain unverified; no new difference or interval is generated.; Reported randomization/double blinding and a no-add-on control without an oral add-on placebo are both retained. Actual fulfillment of participant, assessor or analyst blinding is not established here.; PASI change remains distinct from secondary PASI75, the IL-22 mechanism and quality of life. Secondary/mechanistic signals do not substitute for the selected PASI question's prespecified hierarchy, exact add-on effect or patient importance.; The original record of Indena support and product-related interests is retained. Original funding, product provision, employee authorship, individual COI and research/publication roles remain unread; involvement routes are not newly established or relabeled as absence of support.; Original precautions that 12 weeks cannot exclude long-term hepatic, biliary or bleeding risks, and that soy-lecithin allergy depends on product composition, are retained. Actual events, collection, exposure/denominators, causality, allergy populations and long-term safety remain unverified.; The original evidence date 2026-09-08, correction of 1 English field on 2026-09-14 and stored-material production date 2026-10-06 remain distinct. Actual content-review dates remain unrecorded; PMID, PMCID and bibliographic links are not relabeled as current original-paper reading.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · 2015 · Report of a Meriva add-on trial for psoriasis PASI

PubMed

Material type: Stored description of an add-on trial reported as randomized and double-blind, with a no-add-on control; actual blinding methods and original result tables remain unread
Materials actually read: Stored summary read; external material unread
Findings recorded in the stored summary: Both groups decreased, with a larger decrease in the Meriva add-on arm; exact adjusted CI unverified
Record level: This is retained qualitative add-on-effect wording. Exact group/between-group estimates, intervals, denominators and adjustment remain unverified; it is not relabeled as monotherapy, replacement treatment or a new numerical result.
Study overlap and independent replication: One Meriva add-on report remains distinct from multiple endpoints, additional reports and independent trials. 63 assigned participants and 49 completers are original denominator records; unique-trial/participant totals, formulation-specific independent replication and endpoint-specific analysis denominators remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing trial summary	Existing stored summary acquired	Stored summary	Stored summary read	The stored report/citation summary was read. This does not record possession or abstract/full-text reading of the external original paper. Only the stored summary and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread. URLs and historical abstract narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded.
External paper · Abstract/full text unread	Original bibliography link only; external content unread	Unread; no access attempt	Unread	The original PubMed URL and retained bibliography are linked. PMID/PMCID entries do not establish external identity, abstract/full-text acquisition, accessibility or reading. Only the stored summary and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread. URLs and historical abstract narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded.
Trial registration and amendments	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Actual registration identifiers, contents, prespecification timing and amendments remain unverified. Prespecification is not certified. Only the stored summary and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread. URLs and historical abstract narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded.
Study protocol	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Original study plans for interventions, comparators, endpoint hierarchy, timepoints and amendments remain unread. Only the stored summary and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread. URLs and historical abstract narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded.
Statistical analysis plan	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Original analysis plans for between-group effects, multiplicity, adjustment and ITT/missing-data handling remain unread. Only the stored summary and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread. URLs and historical abstract narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded.
Original funding, product-support, employee-authorship and COI disclosures	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Original funding, product provision, author employment, manufacturer roles and individual COI disclosures remain unread. Retained manufacturer-support wording is not relabeled as completed verification of each route. Only the stored summary and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread. URLs and historical abstract narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded.

Report counts versus independent study counts

One Meriva add-on report remains distinct from multiple endpoints, additional reports and independent trials. 63 assigned participants and 49 completers are original denominator records; unique-trial/participant totals, formulation-specific independent replication and endpoint-specific analysis denominators remain unverified.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which PASI add-on effect is presented?

Required materials and conditions: 12-week PASI with Meriva plus topical steroids versus common topical steroids alone
Conditions for verification: Original records on 12-week PASI with Meriva plus topical steroids versus common topical steroids alone must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on 12-week PASI with Meriva plus topical steroids versus common topical steroids alone is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N02 · Which psoriasis population is included?

Required materials and conditions: Eligibility of adults with mild-to-moderate plaque psoriasis and PASI below 10
Conditions for verification: Original records on Eligibility of adults with mild-to-moderate plaque psoriasis and PASI below 10 must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Eligibility of adults with mild-to-moderate plaque psoriasis and PASI below 10 is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N03 · What are the Meriva carrier and quantified composition?

Required materials and conditions: Commercial phospholipid phytosome, approximately 20% curcuminoids and soy lecithin
Conditions for verification: Original records on Commercial phospholipid phytosome, approximately 20% curcuminoids and soy lecithin must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Commercial phospholipid phytosome, approximately 20% curcuminoids and soy lecithin is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N04 · Is oral Meriva interchangeable with other curcumin products?

Required materials and conditions: Distinguishing oral phospholipid complexes from conventional powder, nano, micellar, piperine-combination and topical products
Conditions for verification: Original records on Distinguishing oral phospholipid complexes from conventional powder, nano, micellar, piperine-combination and topical products must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Distinguishing oral phospholipid complexes from conventional powder, nano, micellar, piperine-combination and topical products is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N05 · What does 2 g/day represent?

Required materials and conditions: 2 g/day of the Meriva product, with actual dosing and adherence
Conditions for verification: Original records on 2 g/day of the Meriva product, with actual dosing and adherence must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on 2 g/day of the Meriva product, with actual dosing and adherence is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N06 · Does benefit persist beyond 12 weeks?

Required materials and conditions: 12 weeks of treatment/follow-up and subsequent persistence/relapse
Conditions for verification: Original records on 12 weeks of treatment/follow-up and subsequent persistence/relapse must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on 12 weeks of treatment/follow-up and subsequent persistence/relapse is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N07 · How was common topical-steroid treatment aligned?

Required materials and conditions: Topical-steroid ingredients, potency, sites, use and changes in both groups
Conditions for verification: Original records on Topical-steroid ingredients, potency, sites, use and changes in both groups must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Topical-steroid ingredients, potency, sites, use and changes in both groups is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N08 · Did the control group receive an oral placebo?

Required materials and conditions: Distinguishing no-add-on controls from add-on-placebo controls
Conditions for verification: Original records on Distinguishing no-add-on controls from add-on-placebo controls must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Distinguishing no-add-on controls from add-on-placebo controls is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N09 · What is the identity of the direct report?

Required materials and conditions: Retained links among the Antiga report title, PMID, PMCID and DOI
Conditions for verification: Original records on Retained links among the Antiga report title, PMID, PMCID and DOI must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Retained links among the Antiga report title, PMID, PMCID and DOI is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N10 · Were registration and a prespecified study plan provided?

Required materials and conditions: Registration identifiers/timing, protocol and amendments
Conditions for verification: Original records on Registration identifiers/timing, protocol and amendments must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Registration identifiers/timing, protocol and amendments is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N11 · What is the hierarchy of PASI change and PASI75?

Required materials and conditions: Distinguishing 12-week PASI change from secondary PASI75 results
Conditions for verification: Original records on Distinguishing 12-week PASI change from secondary PASI75 results must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Distinguishing 12-week PASI change from secondary PASI75 results is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N12 · What were the allocation and concealment methods?

Required materials and conditions: Randomization procedures, allocation concealment and participant flow
Conditions for verification: Original records on Randomization procedures, allocation concealment and participant flow must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Randomization procedures, allocation concealment and participant flow is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N13 · How are reported double blinding and the no-add-on control interpreted?

Required materials and conditions: Blinded parties, maintenance/unblinding and actual control interventions
Conditions for verification: Original records on Blinded parties, maintenance/unblinding and actual control interventions must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Blinded parties, maintenance/unblinding and actual control interventions is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N14 · What denominators do 63 assigned and 49 completed represent?

Required materials and conditions: Distinguishing allocated, completed and endpoint-specific analysis denominators
Conditions for verification: Original records on Distinguishing allocated, completed and endpoint-specific analysis denominators must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Distinguishing allocated, completed and endpoint-specific analysis denominators is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N15 · What does the original 22% attrition describe?

Required materials and conditions: Attrition reasons, distribution by group and the recorded 22%
Conditions for verification: Original records on Attrition reasons, distribution by group and the recorded 22% must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Attrition reasons, distribution by group and the recorded 22% is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N16 · What are the completer analysis and missing-data assumptions?

Required materials and conditions: Results in 49 completers, ITT, missing-data handling and analysis models
Conditions for verification: Original records on Results in 49 completers, ITT, missing-data handling and analysis models must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Results in 49 completers, ITT, missing-data handling and analysis models is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N17 · How was PASI measured?

Required materials and conditions: PASI scoring, baseline values, assessors and 12-week measurement
Conditions for verification: Original records on PASI scoring, baseline values, assessors and 12-week measurement must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on PASI scoring, baseline values, assessors and 12-week measurement is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N18 · What underlies decreases in both groups and the larger add-on decrease?

Required materials and conditions: Group PASI changes and the exact between-group add-on effect
Conditions for verification: Original records on Group PASI changes and the exact between-group add-on effect must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Group PASI changes and the exact between-group add-on effect is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N19 · Is an exact adjusted-effect interval available?

Required materials and conditions: Between-group adjusted PASI estimate and 95% CI
Conditions for verification: Original records on Between-group adjusted PASI estimate and 95% CI must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Between-group adjusted PASI estimate and 95% CI is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N20 · What are the tests, multiplicity and analysis timepoints?

Required materials and conditions: Exact PASI tests, P values, adjustment and prespecified plans
Conditions for verification: Original records on Exact PASI tests, P values, adjustment and prespecified plans must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Exact PASI tests, P values, adjustment and prespecified plans is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N21 · Is the PASI difference clinically important?

Required materials and conditions: Patient importance, responders and quality of life for scale changes
Conditions for verification: Original records on Patient importance, responders and quality of life for scale changes must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Patient importance, responders and quality of life for scale changes is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N22 · Does PASI75 replace the central result?

Required materials and conditions: Denominators, response and intervals for secondary PASI75
Conditions for verification: Original records on Denominators, response and intervals for secondary PASI75 must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Denominators, response and intervals for secondary PASI75 is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N23 · Is IL-22 direction the same outcome as the PASI effect?

Required materials and conditions: Distinguishing the IL-22 mechanistic marker from the PASI clinical scale
Conditions for verification: Original records on Distinguishing the IL-22 mechanistic marker from the PASI clinical scale must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Distinguishing the IL-22 mechanistic marker from the PASI clinical scale is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N24 · Is there independent replication for the same formulation?

Required materials and conditions: Report-to-trial links and formulation-specific independent replication
Conditions for verification: Original records on Report-to-trial links and formulation-specific independent replication must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Report-to-trial links and formulation-specific independent replication is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N25 · What information underlies manufacturer Indena support?

Required materials and conditions: Manufacturer funding, product support and research roles
Conditions for verification: Original records on Manufacturer funding, product support and research roles must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Manufacturer funding, product support and research roles is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N26 · Are product provision, employee authors and COI separately known?

Required materials and conditions: Distinguishing product provision, author employment, COI declarations and funding
Conditions for verification: Original records on Distinguishing product provision, author employment, COI declarations and funding must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Distinguishing product provision, author employment, COI declarations and funding is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N27 · How were short-term adverse events in the same population collected?

Required materials and conditions: Event definitions, collection methods and group exposure denominators
Conditions for verification: Original records on Event definitions, collection methods and group exposure denominators must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Event definitions, collection methods and group exposure denominators is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N28 · Are long-term hepatic, biliary and bleeding risks answered?

Required materials and conditions: Harms beyond 12 weeks, concomitant medicines and long-term follow-up
Conditions for verification: Original records on Harms beyond 12 weeks, concomitant medicines and long-term follow-up must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Harms beyond 12 weeks, concomitant medicines and long-term follow-up is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N29 · What product condition underlies soy-lecithin allergy concerns?

Required materials and conditions: Phospholipid-carrier composition and allergy populations/events
Conditions for verification: Original records on Phospholipid-carrier composition and allergy populations/events must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Phospholipid-carrier composition and allergy populations/events is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N30 · Can findings extend to generic turmeric treatment or steroid replacement?

Required materials and conditions: Distinguishing add-on therapy from monotherapy and treatment replacement
Conditions for verification: Original records on Distinguishing add-on therapy from monotherapy and treatment replacement must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Distinguishing add-on therapy from monotherapy and treatment replacement is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N31 · How are current Korean/English records and the English correction retained?

Required materials and conditions: Current English wording, generic evidence wording and correction of 1 field on 2026-09-14
Conditions for verification: Original records on Current English wording, generic evidence wording and correction of 1 field on 2026-09-14 must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Current English wording, generic evidence wording and correction of 1 field on 2026-09-14 is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N32 · What are C/50, original axes and historical cross-checking?

Required materials and conditions: Original grade, score, axes including I0, E+ and C0, and historical records
Conditions for verification: Original records on Original grade, score, axes including I0, E+ and C0, and historical records must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Original grade, score, axes including I0, E+ and C0, and historical records is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

N33 · What are the original dates, blank fields and actual reading scope?

Required materials and conditions: Original verdict/correction dates, absence of additional selected questions, blank additional-review notes and external unread status
Conditions for verification: Original records on Original verdict/correction dates, absence of additional selected questions, blank additional-review notes and external unread status must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Why this condition is needed: Material on Original verdict/correction dates, absence of additional selected questions, blank additional-review notes and external unread status is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

What the statuses mean

Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
Review incomplete: Review of existing content remains incomplete.
Met: This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.
Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported.
Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned.
Not applicable: Used only with an application exception and reason based on the question scope.
Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work.
Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

Change history

2026-10-24 · Public page/material version 1.0

The public view and materials were prepared from the existing 33 items. No new clinical search, verification-state change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-09-08) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which PASI add-on effect is presented?

Current findings: The original claim concerns PASI improvement in mild-to-moderate plaque psoriasis. Scope is the add-on effect of a specific phospholipid complex alongside topical steroids.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Meriva monotherapy and effects of other formulations are outside this selected question.
Required materials and conditions: 12-week PASI with Meriva plus topical steroids versus common topical steroids alone
Materials to obtain first: Original-trial intervention, comparator and endpoint specifications
Further research: Material needed: Original-trial intervention, comparator and endpoint specifications. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on 12-week PASI with Meriva plus topical steroids versus common topical steroids alone must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on 12-week PASI with Meriva plus topical steroids versus common topical steroids alone is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N02 · Which psoriasis population is included?

Current findings: The retained scope describes adults with mild-to-moderate plaque psoriasis and PASI below 10.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Diagnostic methods, history, baseline characteristics, prior treatments and exclusion criteria remain incompletely verified.
Required materials and conditions: Eligibility of adults with mild-to-moderate plaque psoriasis and PASI below 10
Materials to obtain first: Diagnosis, eligibility and baseline-characteristic tables
Further research: Material needed: Diagnosis, eligibility and baseline-characteristic tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Eligibility of adults with mild-to-moderate plaque psoriasis and PASI below 10 must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Eligibility of adults with mild-to-moderate plaque psoriasis and PASI below 10 is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N03 · What are the Meriva carrier and quantified composition?

Current findings: The retained formulation is a commercial phospholipid phytosome with approximately 20% curcuminoids, using a soy-lecithin carrier.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Product batches, measured composition, manufacturing and bioavailability material remain unverified. Ingredient amounts are not newly converted.
Required materials and conditions: Commercial phospholipid phytosome, approximately 20% curcuminoids and soy lecithin
Materials to obtain first: Product, batch and ingredient-quantification specifications
Further research: Material needed: Product, batch and ingredient-quantification specifications. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Commercial phospholipid phytosome, approximately 20% curcuminoids and soy lecithin must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Commercial phospholipid phytosome, approximately 20% curcuminoids and soy lecithin is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N04 · Is oral Meriva interchangeable with other curcumin products?

Current findings: The selected intervention is oral Meriva. The original record limits interchangeability across other formulations and routes.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Identical effects across other products and routes remain unverified.
Required materials and conditions: Distinguishing oral phospholipid complexes from conventional powder, nano, micellar, piperine-combination and topical products
Materials to obtain first: Direct comparisons for each product and route
Further research: Material needed: Direct comparisons for each product and route. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Distinguishing oral phospholipid complexes from conventional powder, nano, micellar, piperine-combination and topical products must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing oral phospholipid complexes from conventional powder, nano, micellar, piperine-combination and topical products is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N05 · What does 2 g/day represent?

Current findings: The retained dose is 2 g/day of Meriva. It is not equated to 2 g of conventional curcumin.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Actual dosing, adherence, active-ingredient exposure and dose changes remain unverified.
Required materials and conditions: 2 g/day of the Meriva product, with actual dosing and adherence
Materials to obtain first: Product amounts, dosing adherence and change records
Further research: Material needed: Product amounts, dosing adherence and change records. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on 2 g/day of the Meriva product, with actual dosing and adherence must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on 2 g/day of the Meriva product, with actual dosing and adherence is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N06 · Does benefit persist beyond 12 weeks?

Current findings: The retained duration is 12 weeks of treatment and follow-up, with long-term relapse described as unknown.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Post-treatment persistence, relapse and long-term follow-up remain unverified.
Required materials and conditions: 12 weeks of treatment/follow-up and subsequent persistence/relapse
Materials to obtain first: Visit schedules and post-treatment follow-up
Further research: Material needed: Visit schedules and post-treatment follow-up. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on 12 weeks of treatment/follow-up and subsequent persistence/relapse must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on 12 weeks of treatment/follow-up and subsequent persistence/relapse is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N07 · How was common topical-steroid treatment aligned?

Current findings: The record states that both groups used topical steroids and differed by added Meriva.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Topical ingredients, potency, dose, application sites, amounts, changes and rescue treatment remain incompletely verified.
Required materials and conditions: Topical-steroid ingredients, potency, sites, use and changes in both groups
Materials to obtain first: Topical-steroid and rescue-treatment records
Further research: Material needed: Topical-steroid and rescue-treatment records. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Topical-steroid ingredients, potency, sites, use and changes in both groups must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Topical-steroid ingredients, potency, sites, use and changes in both groups is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N08 · Did the control group receive an oral placebo?

Current findings: The original record describes a comparison against topical steroids alone without placebo. The retained evidence also describes a no-add-on control.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Detailed control of expectancy, adherence and concurrent-management differences remains unverified.
Required materials and conditions: Distinguishing no-add-on controls from add-on-placebo controls
Materials to obtain first: Control-intervention, visit and management specifications
Further research: Material needed: Control-intervention, visit and management specifications. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Distinguishing no-add-on controls from add-on-placebo controls must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing no-add-on controls from add-on-placebo controls is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N09 · What is the identity of the direct report?

Current findings: The stored bibliography records Antiga 2015, PMID 26090395, PMCID PMC4450233, DOI 10.1155/2015/283634.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Current external bibliographic/original-file identity and full text remain unread.
Required materials and conditions: Retained links among the Antiga report title, PMID, PMCID and DOI
Materials to obtain first: Original paper and bibliographic records
Further research: Material needed: Original paper and bibliographic records. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Retained links among the Antiga report title, PMID, PMCID and DOI must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Retained links among the Antiga report title, PMID, PMCID and DOI is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N10 · Were registration and a prespecified study plan provided?

Current findings: The retained trial-registration field remains unverified, and the citation contains no registration identifier.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original registration, prespecification timing, protocol and amendment history remain unread.
Required materials and conditions: Registration identifiers/timing, protocol and amendments
Materials to obtain first: Original registration, protocol and amendments
Further research: Material needed: Original registration, protocol and amendments. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Registration identifiers/timing, protocol and amendments must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Registration identifiers/timing, protocol and amendments is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N11 · What is the hierarchy of PASI change and PASI75?

Current findings: The retained endpoint is PASI change at 12 weeks, with PASI75 described as secondary.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: The exact prespecified primary (1st) hierarchy, multiple endpoints and timepoint plans remain unverified.
Required materials and conditions: Distinguishing 12-week PASI change from secondary PASI75 results
Materials to obtain first: Endpoint hierarchy in registration, protocol and SAP
Further research: Material needed: Endpoint hierarchy in registration, protocol and SAP. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Distinguishing 12-week PASI change from secondary PASI75 results must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing 12-week PASI change from secondary PASI75 results is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N12 · What were the allocation and concealment methods?

Current findings: The report is retained as a randomized add-on trial.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Details of allocation sequence, concealment procedures and recruitment flow remain unverified.
Required materials and conditions: Randomization procedures, allocation concealment and participant flow
Materials to obtain first: Allocation methods and participant-flow diagrams
Further research: Material needed: Allocation methods and participant-flow diagrams. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Randomization procedures, allocation concealment and participant flow must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Randomization procedures, allocation concealment and participant flow is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N13 · How are reported double blinding and the no-add-on control interpreted?

Current findings: The retained evidence describes a trial reported as double-blind, with a no-add-on control. Reported wording does not establish actual fulfillment of blinding.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Participant-, assessor- and analyst-specific blinding methods and maintenance remain unverified.
Required materials and conditions: Blinded parties, maintenance/unblinding and actual control interventions
Materials to obtain first: Original blinding-party, placebo and assessment procedures
Further research: Material needed: Original blinding-party, placebo and assessment procedures. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Blinded parties, maintenance/unblinding and actual control interventions must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Blinded parties, maintenance/unblinding and actual control interventions is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N14 · What denominators do 63 assigned and 49 completed represent?

Current findings: The retained sample description is 63 assigned participants and 49 completers. Completer results are not relabeled as analyses of all assigned participants.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Group-specific allocation, completion and analysis counts, and ITT denominators, remain unverified.
Required materials and conditions: Distinguishing allocated, completed and endpoint-specific analysis denominators
Materials to obtain first: Group flow, analysis populations and result tables
Further research: Material needed: Group flow, analysis populations and result tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Distinguishing allocated, completed and endpoint-specific analysis denominators must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing allocated, completed and endpoint-specific analysis denominators is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N15 · What does the original 22% attrition describe?

Current findings: The original record describes 22% attrition. This historical value is retained without recalculation.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Attrition timing, reasons, group distribution and associations with outcomes remain unverified.
Required materials and conditions: Attrition reasons, distribution by group and the recorded 22%
Materials to obtain first: Attrition/discontinuation reasons and group flow
Further research: Material needed: Attrition/discontinuation reasons and group flow. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Attrition reasons, distribution by group and the recorded 22% must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Attrition reasons, distribution by group and the recorded 22% is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N16 · What are the completer analysis and missing-data assumptions?

Current findings: The original record describes positive PASI results among 49 completers.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: ITT status, missing-data handling, adjustment models and sensitivity analyses remain unverified.
Required materials and conditions: Results in 49 completers, ITT, missing-data handling and analysis models
Materials to obtain first: SAP, analysis populations and missing-data material
Further research: Material needed: SAP, analysis populations and missing-data material. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Results in 49 completers, ITT, missing-data handling and analysis models must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Results in 49 completers, ITT, missing-data handling and analysis models is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N17 · How was PASI measured?

Current findings: The selected endpoint is PASI change at 12 weeks.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: PASI measurement procedures, assessor reliability, baseline values and group distributions remain unverified.
Required materials and conditions: PASI scoring, baseline values, assessors and 12-week measurement
Materials to obtain first: Scale, baseline values, assessment procedures and result tables
Further research: Material needed: Scale, baseline values, assessment procedures and result tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on PASI scoring, baseline values, assessors and 12-week measurement must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on PASI scoring, baseline values, assessors and 12-week measurement is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N18 · What underlies decreases in both groups and the larger add-on decrease?

Current findings: The stored result is a narrative of decreases in both groups, with a larger decrease in the Meriva add-on arm.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Exact group changes, between-group estimates and adjustment models are absent from the current summary. A new difference is not generated.
Required materials and conditions: Group PASI changes and the exact between-group add-on effect
Materials to obtain first: Original group tables, between-group effects and analysis output
Further research: Material needed: Original group tables, between-group effects and analysis output. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Group PASI changes and the exact between-group add-on effect must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Group PASI changes and the exact between-group add-on effect is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N19 · Is an exact adjusted-effect interval available?

Current findings: The stored result leaves the exact adjusted CI unverified.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Adjusted estimates, 95% CIs and model details are absent. Denominators alone do not establish precision.
Required materials and conditions: Between-group adjusted PASI estimate and 95% CI
Materials to obtain first: Between-group adjusted estimates, 95% CIs and models
Further research: Material needed: Between-group adjusted estimates, 95% CIs and models. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Between-group adjusted PASI estimate and 95% CI must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Between-group adjusted PASI estimate and 95% CI is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N20 · What are the tests, multiplicity and analysis timepoints?

Current findings: The current summary retains a directionally positive narrative.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Exact P values, multiplicity adjustment, timepoint selection and reporting plans remain unverified.
Required materials and conditions: Exact PASI tests, P values, adjustment and prespecified plans
Materials to obtain first: SAP, all tests and result tables
Further research: Material needed: SAP, all tests and result tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Exact PASI tests, P values, adjustment and prespecified plans must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Exact PASI tests, P values, adjustment and prespecified plans is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N21 · Is the PASI difference clinically important?

Current findings: The retained record centers on PASI and separates quality of life.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Important differences, patient-perceived changes and links to quality-of-life results remain unverified.
Required materials and conditions: Patient importance, responders and quality of life for scale changes
Materials to obtain first: Important-difference, patient-reported and quality-of-life material
Further research: Material needed: Important-difference, patient-reported and quality-of-life material. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Patient importance, responders and quality of life for scale changes must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Patient importance, responders and quality of life for scale changes is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N22 · Does PASI75 replace the central result?

Current findings: PASI75 is retained as a secondary result. It does not replace prespecification or the exact effect for PASI change.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Group-specific PASI75 responders, denominators, exact effects and CIs remain unverified.
Required materials and conditions: Denominators, response and intervals for secondary PASI75
Materials to obtain first: PASI75 result tables and prespecified hierarchy
Further research: Material needed: PASI75 result tables and prespecified hierarchy. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Denominators, response and intervals for secondary PASI75 must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Denominators, response and intervals for secondary PASI75 is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N23 · Is IL-22 direction the same outcome as the PASI effect?

Current findings: The original record describes concordant directions for PASI reduction and IL-22.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Exact IL-22 estimates, prespecified hierarchy and relationship to the clinical scale remain unverified.
Required materials and conditions: Distinguishing the IL-22 mechanistic marker from the PASI clinical scale
Materials to obtain first: Separate mechanistic and PASI result tables
Further research: Material needed: Separate mechanistic and PASI result tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Distinguishing the IL-22 mechanistic marker from the PASI clinical scale must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing the IL-22 mechanistic marker from the PASI clinical scale is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N24 · Is there independent replication for the same formulation?

Current findings: The retained evidence and citation describe one direct report. Multiple outcomes within one report are not counted as multiple trials.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Independent replication and unique-trial/participant totals for the same product, population and add-on regimen remain unverified.
Required materials and conditions: Report-to-trial links and formulation-specific independent replication
Materials to obtain first: Replication reports and trial links under the same conditions
Further research: Material needed: Replication reports and trial links under the same conditions. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Report-to-trial links and formulation-specific independent replication must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Report-to-trial links and formulation-specific independent replication is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N25 · What information underlies manufacturer Indena support?

Current findings: The retained funding description records Indena support and product-related interests.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Support types/amounts and roles in design, analysis, original data and publication remain incompletely verified.
Required materials and conditions: Manufacturer funding, product support and research roles
Materials to obtain first: Original funding, product-support and manufacturer-role disclosures
Further research: Material needed: Original funding, product-support and manufacturer-role disclosures. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Manufacturer funding, product support and research roles must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Manufacturer funding, product support and research roles is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N26 · Are product provision, employee authors and COI separately known?

Current findings: Manufacturer-support wording is retained without establishing product provision, employee authorship or declared COI individually.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Specific documents on individual product support, author affiliations/employment and COI remain unverified.
Required materials and conditions: Distinguishing product provision, author employment, COI declarations and funding
Materials to obtain first: Original product-provision, author-affiliation and COI disclosures
Further research: Material needed: Original product-provision, author-affiliation and COI disclosures. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Distinguishing product provision, author employment, COI declarations and funding must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing product provision, author employment, COI declarations and funding is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N27 · How were short-term adverse events in the same population collected?

Current findings: The retained safety wording limits exclusion of long-term harms from 12-week material.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Short-term adverse-event definitions, collection, group events/denominators and discontinuation reasons remain unverified.
Required materials and conditions: Event definitions, collection methods and group exposure denominators
Materials to obtain first: Adverse-event tables, collection methods and exposure denominators
Further research: Material needed: Adverse-event tables, collection methods and exposure denominators. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Event definitions, collection methods and group exposure denominators must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Event definitions, collection methods and group exposure denominators is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N28 · Are long-term hepatic, biliary and bleeding risks answered?

Current findings: The original record says 12-week material cannot exclude long-term hepatic, biliary or bleeding risks.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Long-term follow-up, concomitant medicines, event comparisons and harm denominators remain unverified.
Required materials and conditions: Harms beyond 12 weeks, concomitant medicines and long-term follow-up
Materials to obtain first: Long-term harm, concomitant-medicine and follow-up material
Further research: Material needed: Long-term harm, concomitant-medicine and follow-up material. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Harms beyond 12 weeks, concomitant medicines and long-term follow-up must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Harms beyond 12 weeks, concomitant medicines and long-term follow-up is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N29 · What product condition underlies soy-lecithin allergy concerns?

Current findings: The retained record describes a soy-lecithin carrier and allergy checks depending on product composition.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Trial allergy-exclusion criteria, events and exact product ingredient lists remain unverified.
Required materials and conditions: Phospholipid-carrier composition and allergy populations/events
Materials to obtain first: Product composition, allergy criteria and event material
Further research: Material needed: Product composition, allergy criteria and event material. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Phospholipid-carrier composition and allergy populations/events must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Phospholipid-carrier composition and allergy populations/events is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N30 · Can findings extend to generic turmeric treatment or steroid replacement?

Current findings: The original record limits extension to treatment with dietary turmeric/generic powder or replacement of topical steroids.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Direct comparisons on monotherapy effects, treatment discontinuation/replacement and other products remain unverified.
Required materials and conditions: Distinguishing add-on therapy from monotherapy and treatment replacement
Materials to obtain first: Direct monotherapy and replacement-treatment comparisons
Further research: Material needed: Direct monotherapy and replacement-treatment comparisons. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Distinguishing add-on therapy from monotherapy and treatment replacement must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing add-on therapy from monotherapy and treatment replacement is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N31 · How are current Korean/English records and the English correction retained?

Current findings: Current Korean/English material and the correction of 1 English field are retained. Generic English wording does not substitute for verification of exact numbers or denominators.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Historical before/after English and full-text alignment remain incompletely verified from current inputs alone.
Required materials and conditions: Current English wording, generic evidence wording and correction of 1 field on 2026-09-14
Materials to obtain first: Before/after-correction and language-alignment material
Further research: Material needed: Before/after-correction and language-alignment material. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Current English wording, generic evidence wording and correction of 1 field on 2026-09-14 must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Current English wording, generic evidence wording and correction of 1 field on 2026-09-14 is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N32 · What are C/50, original axes and historical cross-checking?

Current findings: C/50, all axes and historical cross-checking wording are retained as historical values. They are not inherited as completed current content review or fulfilled conditions.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Completed content review is not recorded in the retained material.
Required materials and conditions: Original grade, score, axes including I0, E+ and C0, and historical records
Materials to obtain first: Review comments and future correction material
Further research: Material needed: Review comments and future correction material. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Original grade, score, axes including I0, E+ and C0, and historical records must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original grade, score, axes including I0, E+ and C0, and historical records is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01

N33 · What are the original dates, blank fields and actual reading scope?

Current findings: The full retained record was used for preparation. Original verdict date 2026-09-08, correction date 2026-09-14 and blank original values remain preserved.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: External abstracts, full texts, registration, protocols and SAPs remain unread, with no access attempt.
Required materials and conditions: Original verdict/correction dates, absence of additional selected questions, blank additional-review notes and external unread status
Materials to obtain first: Needed original material and study plans when provided
Further research: Material needed: Needed original material and study plans when provided. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Original verdict/correction dates, absence of additional selected questions, blank additional-review notes and external unread status must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original verdict/correction dates, absence of additional selected questions, blank additional-review notes and external unread status is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope.
Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety.
Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record.

Related sources S01